PharmaNet Hosts Observational Research Symposium in Zurich
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
During this symposium, PharmaNet and industry experts will discuss the challenges of "real world" observational research, one of the fastest growing areas of clinical research. Actual case studies will be examined to reveal optimal approaches for establishing safety and value in the post-approval environment. Topics will include:
• Data from Observational Studies: Sufficient Evidence of Economic Value? Ruth McAllister, Consultant Health Economist, Abacus International, and David Schwicker, Managing Director, Phase IV Programs LLC
• Issues in Observational Research: Operational Implications, Jeff Trotter, Executive Vice President, Phase IV Development, PharmaNet
• Observational Studies and Patient Registries: Operational Approach, Ron Weishaar, Executive Director, Observational Research, Phase IV Development, PharmaNet
• Stakeholder Perspectives: EMA / Payors, Andrew Roddam, International Head, Center for Observational Research, Amgen UK
• Case Studies in Patient Registries, Matthew Gordon, Senior Director, Patient Registries, PharmaNet
• Technological Change and Implications for Observational Research, Ken Ashman, Executive Director, Phase IV European Operations, PharmaNet
If you would like to attend, please contact Patricia Hall
• Data from Observational Studies: Sufficient Evidence of Economic Value? Ruth McAllister, Consultant Health Economist, Abacus International, and David Schwicker, Managing Director, Phase IV Programs LLC
• Issues in Observational Research: Operational Implications, Jeff Trotter, Executive Vice President, Phase IV Development, PharmaNet
• Observational Studies and Patient Registries: Operational Approach, Ron Weishaar, Executive Director, Observational Research, Phase IV Development, PharmaNet
• Stakeholder Perspectives: EMA / Payors, Andrew Roddam, International Head, Center for Observational Research, Amgen UK
• Case Studies in Patient Registries, Matthew Gordon, Senior Director, Patient Registries, PharmaNet
• Technological Change and Implications for Observational Research, Ken Ashman, Executive Director, Phase IV European Operations, PharmaNet
If you would like to attend, please contact Patricia Hall
